NCT05418088 2025-05-16Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesOhio State University Comprehensive Cancer CenterPhase 1 Recruiting54 enrolled